Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585511 | 1.00 | DRD4 (0.58) | DRD4SIGMAR1HTR1ACYP1A2CYP3A4 | |
| SCHEMBL2947770 | 0.83 | MC4R (0.58) | SIGMAR1HTR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2947772 | 0.83 | MC4R (0.58) | SIGMAR1HTR1ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3588462 | 0.82 | SIGMAR1 (0.49) | SIGMAR1HTR1ACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3588458 | 0.82 | SIGMAR1 (0.49) | SIGMAR1HTR1ACYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3585408 | 0.81 | CCR2 (0.52) | HTR1AALDH1A1CCR2KCNH2 | |
| SCHEMBL3585412 | 0.81 | CCR2 (0.52) | HTR1AALDH1A1CCR2KCNH2 | |
| SCHEMBL8176746 | 0.81 | SIGMAR1 (0.62) | SIGMAR1HTR1ACCR3 | |
| SCHEMBL3595224 | 0.78 | CCR2 (0.55) | SIGMAR1HTR1AALDH1A1CCR2KCNH2 | |
| SCHEMBL3595227 | 0.78 | CCR2 (0.55) | SIGMAR1HTR1AALDH1A1CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825112-B2 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| CN-101365698-A | 2-urea-4-phenylthiazole derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-11 | — | — | CN | disclosed |
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | US | disclosed |
| EP-1984361-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007077394-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018117-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PKD2, QPCT, CCNT2 | DRD4 1149/4885SIGMAR1 1047/4885HTR1A 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.